基于数据驱动的骨髓增生异常综合征统一分类系统:国际骨髓增生异常综合征联盟共识文件
国际骨髓增生异常综合征联盟采用数据驱动方法和改良德尔菲共识流程,协调WHO与ICC 2022两套MDS分类系统。研究识别出九个具有独特基因组特征的聚类,其中双等位TP53失活聚类层级最高且不依赖原始细胞计数。该数据驱动方法可有效统一现有MDS分类并为真实世界患者管理提供参考。
要点
- 双等位TP53失活是层级最高的聚类,其聚类分配与原始细胞计数无关。
- 伴del(5q)的MDS层级第二,孤立性del(5q)且骨髓原始细胞<5%是最相关标签定义特征。
- 伴SF3B1突变的MDS层级第三,其统一标签需排除孤立性del(5q)、del(7q)/-7、abn3q26.2、复杂核型、RUNX1突变或双等位TP53。
核心结论
- 数据驱动方法可有效统一当前骨髓增生异常综合征分类,并为真实世界患者管理提供参考。
研究设计与样本
- 国际骨髓增生异常综合征联盟组建血液科医生、血液病理学家和数据科学家专家组,采用改良德尔菲共识流程,举行定期在线会议并进行两轮在线投票调查。
主要发现
- 识别出九个具有独特基因组特征的聚类,其中双等位TP53失活聚类层级最高且聚类分配与原始细胞计数无关,单等位TP53失活个体被分配至其他聚类。
- 层级第二的聚类为伴del(5q)的骨髓增生异常综合征,孤立性del(5q)且骨髓原始细胞小于5%是最相关标签定义特征。
- 层级第三的聚类为伴SF3B1突变的骨髓增生异常综合征,其统一标签基于排除孤立性del(5q)、del(7q)/-7、abn3q26.2、复杂核型、RUNX1突变或双等位TP53。
- 形态学定义的骨髓增生异常综合征实体显示大规模基因组异质性,单系与多系发育异常、骨髓原始细胞、低细胞性或纤维化未能有效捕获该异质性。
- 伴超过10%骨髓原始细胞的骨髓增生异常综合征与急性髓系白血病之间的生物学连续体仅显示部分遗传特征重叠;调查后,低原始细胞(即小于5%)的骨髓增生异常综合征和原始细胞增多(即5%或以上)的骨髓增生异常综合征被认定为疾病实体。
关键数值与推荐
- 双等位TP53失活聚类层级最高,聚类分配与原始细胞计数无关;单等位TP53失活者归入其他聚类。
- 伴del(5q)的骨髓增生异常综合征层级第二,孤立性del(5q)且骨髓原始细胞小于5%为最相关标签定义特征。
- 伴SF3B1突变的骨髓增生异常综合征层级第三,统一标签需排除孤立性del(5q)、del(7q)/-7、abn3q26.2、复杂核型、RUNX1突变或双等位TP53。
- 低原始细胞(即小于5%)的骨髓增生异常综合征和原始细胞增多(即5%或以上)的骨髓增生异常综合征被认定为疾病实体。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The WHO and International Consensus Classification 2022 classifications of myelodysplastic syndromes enhance diagnostic precision and refine decision-making processes in these diseases. However, some discrepancies still exist and potentially cause inconsistency in their adoption in a clinical setting. We adopted a data-driven approach to provide a harmonisation between these two classification systems. We investigated the importance of genomic features and their effect on the cluster assignment process to define harmonised entity labels. A panel of expert haematologists, haematopathologists, and data scientists who are members of the International Consortium for Myelodysplastic Syndromes was formed and a modified Delphi consensus process was adopted to harmonise morphologically defined categories without a distinct genomic profile. The panel held regular online meetings and participated in a two-round survey using an online voting tool. We identified nine clusters with distinct genomic features. The cluster of highest hierarchical importance was characterised by biallelic TP53 inactivation. Cluster assignment was irrespective of blast count. Individuals with monoallelic TP53 inactivation were assigned to other clusters. Hierarchically, the second most important group included myelodysplastic syndromes with del(5q). Isolated del(5q) and less than 5% of blast cells in the bone marrow were the most relevant label-defining features. The third most important cluster included myelodysplastic syndromes with mutated SF3B1. The absence of isolated del(5q), del(7q)/-7, abn3q26.2, complex karyotype, RUNX1 mutations, or biallelic TP53 were the basis for a harmonised label of this category. Morphologically defined myelodysplastic syndrome entities showed large genomic heterogeneity that was not efficiently captured by single-lineage versus multilineage dysplasia, marrow blasts, hypocellularity, or fibrosis. We investigated the biological continuum between myelodysplastic syndromes with more than 10% bone marrow blasts and acute myeloid leukaemia, and found only a partial overlap in genetic features. After the survey, myelodysplastic syndromes with low blasts (ie, less than 5%) and myelodysplastic syndromes with increased blasts (ie, 5% or more) were recognised as disease entities. Our data-driven approach can efficiently harmonise current classifications of myelodysplastic syndromes and provide a reference for patient management in a real-world setting.
引用
- Komrokji RS, Lanino L, Ball S, et al. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes. Lancet Haematol. 2024. PMID: 39393368. doi:10.1016/S2352-3026(24)00251-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。